AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

Contributed by: PR Newswire

Tags

AnnJi-Pharma-Announce

More Like This

Exidavnemab phase 2a study expanded to include MSA patients

Business Wire logo

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

PR Newswire associated0

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

ACCESS Newswire logo

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

BioArctic receives Orphan Drug Designation for exidavnemab the US

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort